Raleigh’s Aceragen, Arrevus Combine Forces to Tackle Rare Diseases
Raleigh-based Aceragen, a biopharmaceutical company developing therapeutics for rare and orphan diseases, has acquired Arrevus, another Raleigh company with a similar focus.
In order for the Aceragen website to work properly, we place functional cookies. Aceragen also places analytical cookies to determine which parts of the website are most interesting for you as visitors. In addition, Aceragen uses cookies to analyze our ads and traffic and to provide social media features.